Phase 3 zavegepant trial demonstrates acute pain relief in migraine Galcanezumab and rimegepant go head-to-head in CHALLENGE-MIG study HER-MES data support superiority of erenumab over topiramate in migraine prevention European biomarker study seeks response indicators for CGRP mAbs Ligand- and receptor-binding CGRP mAbs are equally effective Changing migraine patterns after erenumab and influence of personality and stress Response to fremanezumab in Korean patients compares well with pivotal HALO studies Rapid effects of CGRP mAbs highlighted in real world study

Partnership & Outreach

Through its unique global network of researchers and clinicians, the CGRP Education and Research Forum connects academic institutions, research organisations and societies which share the Forum’s commitment to the reduction of the burden, disability and cost associated with migraine.

Educational Partners and Supporters (others pending) Amgen

Amgen

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2022 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach |